MX340112B - Composicion que comprende un agonista de receptor de serotonina y una dicetopiperazina para el tratamiento de migrañas. - Google Patents

Composicion que comprende un agonista de receptor de serotonina y una dicetopiperazina para el tratamiento de migrañas.

Info

Publication number
MX340112B
MX340112B MX2013005294A MX2013005294A MX340112B MX 340112 B MX340112 B MX 340112B MX 2013005294 A MX2013005294 A MX 2013005294A MX 2013005294 A MX2013005294 A MX 2013005294A MX 340112 B MX340112 B MX 340112B
Authority
MX
Mexico
Prior art keywords
diketopiperazine
composition
receptor agonist
serotonin receptor
treating migraines
Prior art date
Application number
MX2013005294A
Other languages
English (en)
Other versions
MX2013005294A (es
Inventor
Leone-Bay Andrea
Grant Marshall
C Smutney Chad
W Stowell Grayson
J Guarneri Joseph
M Carlson Dawn
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mannkind Corp filed Critical Mannkind Corp
Publication of MX2013005294A publication Critical patent/MX2013005294A/es
Publication of MX340112B publication Critical patent/MX340112B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe un método para el tratamiento de migrañas. El método utiliza un sistema de suministro rápido de fármaco, el cual evita la desactivación o degradación del agente activo, incluyendo moléculas pequeñas y péptidos que se administran a un paciente con la necesidad del tratamiento. En particular, el sistema de suministro de fármaco está diseñado para suministrar fármacos al la circulación pulmonar en una forma rápida y terapéuticamente efectiva.
MX2013005294A 2010-11-09 2011-11-09 Composicion que comprende un agonista de receptor de serotonina y una dicetopiperazina para el tratamiento de migrañas. MX340112B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41177510P 2010-11-09 2010-11-09
US41233910P 2010-11-10 2010-11-10
PCT/US2011/060057 WO2012064892A1 (en) 2010-11-09 2011-11-09 Composition comprising a serotonin receptor agonist and a diketopiperazine for treating migraines

Publications (2)

Publication Number Publication Date
MX2013005294A MX2013005294A (es) 2013-12-06
MX340112B true MX340112B (es) 2016-06-27

Family

ID=45048258

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005294A MX340112B (es) 2010-11-09 2011-11-09 Composicion que comprende un agonista de receptor de serotonina y una dicetopiperazina para el tratamiento de migrañas.

Country Status (10)

Country Link
EP (2) EP3536368A1 (es)
JP (2) JP6092113B2 (es)
KR (1) KR101931392B1 (es)
CN (2) CN107854454A (es)
AU (1) AU2011326529B2 (es)
BR (1) BR112013011549B1 (es)
CA (1) CA2817337C (es)
ES (1) ES2732818T3 (es)
MX (1) MX340112B (es)
WO (1) WO2012064892A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
WO2003080149A2 (en) 2002-03-20 2003-10-02 Mannkind Corporation Inhalation apparatus
DE602005024413D1 (de) 2004-08-20 2010-12-09 Mannkind Corp Katalyse der diketopiperazinsynthese
ES2540886T3 (es) 2004-08-23 2015-07-14 Mannkind Corporation Sales de dicetopiperazina para la administración de fármacos
KR101557502B1 (ko) 2005-09-14 2015-10-06 맨카인드 코포레이션 결정질 미립자 표면에 대한 활성제의 친화력의 증가를기반으로 하는 약물 제제의 방법
AU2007216966C1 (en) 2006-02-22 2014-03-20 Mannkind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
PL2293833T3 (pl) 2008-06-13 2016-08-31 Mannkind Corp Inhalator proszkowy i układ do dostarczania leku
EP2609954B1 (en) 2008-06-20 2021-12-29 MannKind Corporation An interactive apparatus for real-time profiling of inhalation efforts
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2405963B1 (en) 2009-03-11 2013-11-06 MannKind Corporation Apparatus, system and method for measuring resistance of an inhaler
KR20180079458A (ko) 2009-06-12 2018-07-10 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
US9016147B2 (en) 2009-11-03 2015-04-28 Mannkind Corporation Apparatus and method for simulating inhalation efforts
CA2801936C (en) 2010-06-21 2021-06-01 Mannkind Corporation Dry powder drug delivery system and methods
EP2694402B1 (en) 2011-04-01 2017-03-22 MannKind Corporation Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
EP2776053A1 (en) 2011-10-24 2014-09-17 MannKind Corporation Methods and compositions for treating pain
AU2013289957B2 (en) 2012-07-12 2017-02-23 Mannkind Corporation Dry powder drug delivery systems and methods
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
AR094180A1 (es) 2012-12-21 2015-07-15 Sanofi Sa Derivados de exendina-4
KR102499439B1 (ko) 2013-03-15 2023-02-13 맨카인드 코포레이션 미세결정성 디케토피페라진 조성물 및 방법
MX2020009878A (es) 2013-07-18 2022-07-27 Mannkind Corp Composiciones farmaceuticas en polvo seco estables al calor y metodos.
JP2016530930A (ja) 2013-08-05 2016-10-06 マンカインド コーポレイション 通気装置及び方法
CN103599155B (zh) * 2013-11-27 2015-12-02 广州安健实业发展有限公司 治疗偏头痛的方法
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
CA2984339A1 (en) * 2015-05-01 2016-11-10 Civitas Therapeutics, Inc. Zolmitriptan powders for pulmonary delivery
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AU2016287582B2 (en) 2015-07-02 2020-03-12 Civitas Therapeutics, Inc. Triptan powders for pulmonary delivery
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
GB201709459D0 (en) * 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
US11135379B2 (en) 2019-02-15 2021-10-05 Bn Intellectual Properties, Inc. Method of delivering pharmaceutical products
US11364225B2 (en) * 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
GB9827145D0 (en) * 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
US7305986B1 (en) 1999-07-23 2007-12-11 Mannkind Corporation Unit dose capsules for use in a dry powder inhaler
US7464706B2 (en) 1999-07-23 2008-12-16 Mannkind Corporation Unit dose cartridge and dry powder inhaler
CN1176649C (zh) * 2002-10-16 2004-11-24 上海医药工业研究院 舒马普坦干粉吸入剂及其制备方法
ES2540886T3 (es) 2004-08-23 2015-07-14 Mannkind Corporation Sales de dicetopiperazina para la administración de fármacos
KR101557502B1 (ko) 2005-09-14 2015-10-06 맨카인드 코포레이션 결정질 미립자 표면에 대한 활성제의 친화력의 증가를기반으로 하는 약물 제제의 방법
AU2007216966C1 (en) * 2006-02-22 2014-03-20 Mannkind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
ES2547529T3 (es) * 2007-10-24 2015-10-07 Mannkind Corporation Formulación en polvo seco inhalable que comprende GLP-1 para usar en el tratamiento de la hiperglucemia y diabetes por administración pulmonar
KR20130123470A (ko) * 2007-10-24 2013-11-12 맨카인드 코포레이션 활성제의 전달
JP2011510964A (ja) * 2008-02-01 2011-04-07 ヴェクトゥラ リミテッド トリプタン類の肺用製剤
PL2293833T3 (pl) 2008-06-13 2016-08-31 Mannkind Corp Inhalator proszkowy i układ do dostarczania leku

Also Published As

Publication number Publication date
JP2013545748A (ja) 2013-12-26
EP3536368A1 (en) 2019-09-11
WO2012064892A1 (en) 2012-05-18
CN107854454A (zh) 2018-03-30
CA2817337A1 (en) 2012-05-18
AU2011326529A1 (en) 2013-05-02
MX2013005294A (es) 2013-12-06
JP6458064B2 (ja) 2019-01-23
EP2637657B1 (en) 2019-05-22
KR20140008314A (ko) 2014-01-21
EP2637657A1 (en) 2013-09-18
JP6092113B2 (ja) 2017-03-08
CN103200940A (zh) 2013-07-10
AU2011326529B2 (en) 2015-07-30
BR112013011549B1 (pt) 2022-01-04
ES2732818T3 (es) 2019-11-26
JP2017110026A (ja) 2017-06-22
CA2817337C (en) 2020-04-14
KR101931392B1 (ko) 2018-12-20
BR112013011549A2 (pt) 2017-07-25

Similar Documents

Publication Publication Date Title
MX340112B (es) Composicion que comprende un agonista de receptor de serotonina y una dicetopiperazina para el tratamiento de migrañas.
IN2014DN03093A (es)
EA200802012A1 (ru) Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
BRPI1011220A2 (pt) composição farmacêutica, métodos para tratar uma doença ou distúrbio, para administração respiratória de dois ou mais agentes ativos, para administração respiratória de uma combinação de agentes ativos, e, para preparar uma composição adequada.
JP2012041342A5 (es)
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
SA520411119B1 (ar) تركيبات جسيم شحمي تشمل عقاقير مكونة من حمض ضعيف واستخداماتها
MX2015005798A (es) Terapia de combinacion.
MX2015000538A (es) Sistemas y metodos de suministro de farmaco en polvo seco.
MX2019012884A (es) Terapia de combinacion.
MX352824B (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación.
UA115139C2 (uk) Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
EA201490149A1 (ru) Композиция и лекарственное средство, содержащие рекомбинантную человеческую идуронат-2-сульфатазу, и способ их получения
MX2019003173A (es) Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada.
EA032951B1 (ru) Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения
MX2013014461A (es) Formulaciones de liberacion sostenida para el suministro de proteinas al ojo y metodos para prepararlas.
MD4369B1 (ro) Utilizarea glicopirolatului pentru tratarea tahicardiei, doză unică, dispozitiv de administrare, metodă de tratament şi profilaxie a tahicardiei
WO2010151565A3 (en) Combination therapies for the treatment of obesity
NZ600583A (en) Visfatin therapeutic agents for the treatment of acne and other conditions
MX367070B (es) Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.
MX2014013256A (es) Formulaciones de acido poliinosinico-policitidilico (poli(i:c)) para el tratamiento de infecciones de las vias respiratorias altas.
EA200802350A2 (ru) Система доставки лекарств
RU2017124487A (ru) НОВЫЙ ПЕПТИД-ИНГИБИТОР PI3Kγ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ОРГАНОВ ДЫХАНИЯ
EA201290278A1 (ru) Способ лечения сердечной недостаточности с использованием стресскопинподобных пептидов

Legal Events

Date Code Title Description
FG Grant or registration